Welcome to our dedicated page for Annexon news (Ticker: ANNX), a resource for investors and traders seeking the latest updates and insights on Annexon stock.
Annexon, Inc. (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company that focuses on developing novel therapeutics aimed at treating complement-mediated neurodegenerative and autoimmune diseases. The company's unique scientific approach targets C1q, the initiating molecule of the classical complement pathway, to halt the inflammatory cascade before it starts, providing significant potential benefits across a range of diseases affecting the body, brain, and eye.
Annexon’s primary product candidates include:
- ANX005: A monoclonal antibody designed to block C1q, currently in pivotal Phase 3 trials for Guillain-Barré Syndrome (GBS) and showing promising results in reducing muscle strength loss and nerve damage.
- ANX007: An antigen-binding fragment aimed at treating geographic atrophy (GA) in the eye, demonstrating notable protection against vision loss and retinal damage in Phase 2 trials.
- ANX1502: An oral small molecule inhibitor targeting autoimmune diseases, expected to generate proof-of-concept data in the second half of 2024.
In recent developments, Annexon announced positive top-line results from their Phase 3 trial of ANX005 in GBS, showing significant improvements in clinical outcomes and muscle strength. This trial marks a major milestone as ANX005 could become the first targeted treatment for GBS in the U.S. The company also showcased ANX007's potential in preserving retinal structures and vision in GA patients, with Phase 3 trials set to commence in 2024.
Financially, Annexon maintains a robust balance sheet with approximately $260 million in cash and equivalents, providing a runway into mid-2026. The company recently completed a public offering to raise additional capital, further strengthening its financial position to advance its clinical programs.
Annexon continues to advance its pipeline rigorously, with multiple upcoming milestones that have the potential to generate substantial value for patients and shareholders alike.
Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company, announced the granting of equity inducement awards to three new non-executive employees under its 2022 Employment Inducement Award Plan. This decision, made on September 15, 2022, complies with Nasdaq Listing Rule 5635(c)(4). The new employees received options to purchase a total of 125,000 shares of common stock, at an exercise price of $6.34 per share. The options have a ten-year term and will vest over four years, with the first 25% vesting on the first anniversary of their employment.
Annexon, Inc. (Nasdaq: ANNX) announced the granting of equity inducement awards to three new non-executive employees under its 2022 Employment Inducement Award Plan. Approved on August 16, 2022, the awards total 172,000 shares of common stock in options with a ten-year term and an exercise price of $5.83. Vesting will occur over four years, starting 25% on the first anniversary of employment. Annexon is dedicated to developing innovative complement medicines for autoimmune, neurodegenerative, and ophthalmic disorders.
Annexon, a clinical-stage biopharmaceutical company focused on complement-mediated diseases, reported significant progress with five clinical-stage candidates following recent Phase 1 trial initiations for ANX105 and ANX1502. The company secured approximately $130 million in a private placement, extending its operating runway into the second half of 2025. The FDA granted Fast Track designation for ANX007 targeting geographic atrophy. Despite a net loss of $37.1 million in Q2 2022, the promising pipeline and anticipated clinical milestones are set to drive future growth.
Annexon, Inc. (Nasdaq: ANNX) has completed a private placement, raising approximately $130 million to support its clinical pipeline of complement medicines for autoimmune, neurodegenerative, and ophthalmic disorders. This funding will extend the company’s operational runway into the second half of 2025. The placement includes the sale of 9,013,834 shares and pre-funded warrants at prices around $3.87 per share. Major investors include Redmile Group, Adage Capital, and Bain Capital. Annexon aims to advance its first oral complement agent, ANX1502.
Annexon, a clinical-stage biopharmaceutical company, announced a private placement expected to raise approximately $130 million before fees. The placement involves selling 9,013,834 shares of common stock and warrants, priced at $3.871250 per share. Major investors include Redmile Group and Adage Capital. The deal will close on July 11, 2022, pending customary conditions. The company is committed to filing a registration statement for resale of the shares, aligning with Nasdaq regulations.
Annexon (Nasdaq: ANNX) announced positive final data from its Phase 2 clinical trial of ANX005 for Huntington’s disease (HD), showing complete C1q target inhibition and stabilization of disease progression over nine months. Of 28 participants, 23 completed the study, demonstrating sustained clinical benefits in patients with high baseline complement activity. The treatment was generally well-tolerated, with no serious adverse events reported. These results highlight ANX005’s potential as a novel therapy for HD, addressing a critical unmet need in the field.
Annexon (Nasdaq: ANNX), a clinical-stage biopharmaceutical company, announced that CEO Douglas Love will present at the 2022 Jefferies Healthcare Conference on June 9, 2022, at 10:30 a.m. ET in New York City. The event is part of Annexon's effort to showcase its innovative complement medicines targeting autoimmune, neurodegenerative, and ophthalmic disorders. A live webcast will be available on the company's Investors page, with a 30-day replay option.
Annexon is developing a diverse pipeline aimed at treating classical complement-mediated diseases.
Annexon, Inc. (Nasdaq: ANNX) announced plans to present data from its complement-targeted pipeline at various medical meetings this summer. The company focuses on developing treatments for classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders. Key presentations include topics related to lupus nephritis and warm autoimmune hemolytic anemia, scheduled for June 2022. Annexon's approach aims to inhibit C1q, offering potential protection against diseases impacted by the classical complement pathway, with clinical data expected throughout 2022 and 2023.
Annexon, a clinical-stage biopharmaceutical company, reported progress across its pipeline and first quarter 2022 financial results. With a broad portfolio of five candidates targeting complement-mediated disorders, Annexon anticipates eight clinical catalysts in 2022-2023. The lead candidate, ANX005, shows promise in treating Guillain-Barré Syndrome and Huntington's disease, demonstrating rapid clinical improvements. As of March 31, 2022, cash reserves totaled $206.7 million, sufficient to fund operations into 2024. However, the company reported a net loss of $35.4 million, reflecting increased expenses.
Annexon, Inc. (Nasdaq: ANNX) announced that CEO Douglas Love will participate in upcoming investor conferences: the BofA Securities 2022 Healthcare Conference on May 12, 2022, in Las Vegas, and the H.C. Wainwright Global Investment Conference on May 25, 2022, in Miami. The company specializes in developing complement-targeting medicines for autoimmune, neurodegenerative, and ophthalmic disorders. Webcasts of the events will be available on the company's website for 30 days post-conference. Annexon is advancing several clinical-stage candidates, including ANX005, ANX007, and ANX009.
FAQ
What is the current stock price of Annexon (ANNX)?
What is the market cap of Annexon (ANNX)?
What does Annexon, Inc. specialize in?
What are Annexon's main product candidates?
What recent achievements has Annexon announced?
What is the financial condition of Annexon?
When are the next key milestones expected for Annexon’s pipeline?
What is the scientific approach of Annexon?
What is the potential impact of ANX007 on GA patients?
How does ANX005 work in treating GBS?
What regulatory designations has ANX005 received?
Where can I find more information about Annexon?
